Literature DB >> 12664753

An audit of the investigation and use of anti-D immunoglobulin prophylaxis in Tayside.

I Rennie1, A Smith, R Smith, P S Rawlinson, P Clark.   

Abstract

OBJECTIVES: To audit the implementation of national guidelines on the investigation and management of RhD disease in Tayside.
SETTING: Tayside region.
DESIGN: An eight month retrospective audit.
RESULTS: Two hundred and eighty eight completed pregnancies in RhD negative women were observed from a total of 1879 deliveries. Of these, 120 RhD negative and 169 RhD positive babies were delivered from women who had not previously been sensitised. At delivery, anti-D was used appropriately in all cases. Of those assessed to require anti-D (n = 168), 91% received it within 24 hours of delivery. In 59 RhD negative subjects, 75 potential sensitising events occurred antenatally. In 45 of these, the event occurred after 20 weeks gestation and 44 received appropriate anti-D. In 11 (23.7%) of these, no foetomaternal haemorrhage assessment was carried out.
CONCLUSION: Despite a significant increase in awareness of antenatal prophylaxis since a previous audit in the region, there is still a significant failure to request FMH assessments following potential antenatal sensitising episodes and after delivery. During the audit period, an EDTA plasma gell-based antibody detection system was commissioned in the region. This has allowed the introduction of internal laboratory referral for FMH assessment. This has allowed accurate knowledge on the possible occurrence of FMH at delivery, but has not had a significant impact on antenatal events.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 12664753

Source DB:  PubMed          Journal:  Health Bull (Edinb)        ISSN: 0374-8014


  1 in total

Review 1.  Appropriate provision of anti-D prophylaxis to RhD negative pregnant women: a scoping review.

Authors:  Trina M Fyfe; M Jane Ritchey; Christorina Taruc; Daniel Crompton; Brian Galliford; Rose Perrin
Journal:  BMC Pregnancy Childbirth       Date:  2014-12-10       Impact factor: 3.007

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.